Table 1. Demographic, clinical, exposure, and investigation characteristics among actively monitored close contacts with at least basic data on exposures to 9 confirmed COVID-19 patients, United States, January–February 2020.
| Household N (%) | Healthcare Personnel* N (%) | Community: Healthcare Setting N (%) | Community: Other Setting N (%) | |
|---|---|---|---|---|
| N | 15 | 163 | 95 | 65 |
| Demographics | ||||
| Sex | ||||
| Female | 6 (40.0) | 106 (65.0) | 40 (42.1) | 27 (41.5) |
| Male | 9 (60.0) | 35 (21.5) | 28 (29.5) | 32 (49.2) |
| Missing Sex Information | 0 (0.0) | 22 (13.5) | 27 (28.4) | 6 (9.2) |
| Age Category | ||||
| < 10 years | 1 (6.7) | 0 (0.0) | 6 (6.3) | 0 (0.0) |
| 10–17 years | 1 (6.7) | 0 (0.0) | 4 (4.2) | 0 (0.0) |
| 18–44 years | 7 (46.7) | 101 (62.0) | 24 (25.3) | 20 (30.8) |
| 45–64 years | 5 (33.3) | 40 (24.5) | 16 (16.8) | 12 (18.5) |
| 65+ years | 1 (6.7) | 2 (1.2) | 10 (10.5) | 1 (1.5) |
| Missing Age Information | 0 (0.0) | 20 (12.3) | 35 (36.8) | 32 (49.2) |
| Race / Ethnicity | ||||
| White, Non-Hispanic | 0 (0.0) | 68 (41.7) | 22 (23.2) | 9 (13.8) |
| Black, Non-Hispanic | 0 (0.0) | 4 (2.5) | 0 (0.0) | 0 (0.0) |
| Hispanic / Latino | 0 (0.0) | 33 (20.2) | 12 (12.6) | 0 (0.0) |
| Asian | 7 (46.7) | 39 (23.9) | 8 (8.4) | 13 (20.0) |
| Other | 0 (0.0) | 2 (1.2) | 0 (0.0) | 0 (0.0) |
| Missing Race / Ethnicity Information | 8 (53.3) | 17 (10.4) | 53 (55.8) | 43 (66.2) |
| Medical History | ||||
| Smoking History | ||||
| Current | 3 (20.0) | 2 (1.2) | 2 (2.1) | 2 (3.1) |
| Former | 0 (0.0) | 10 (6.1) | 4 (4.2) | 3 (4.6) |
| Never | 4 (26.7) | 22 (13.5) | 15 (15.8) | 25 (38.5) |
| Missing Smoking Information | 8 (53.3) | 129 (79.1) | 74 (77.9) | 35 (53.8) |
| Cardiovascular Disease | ||||
| No History | 4 (26.7) | 33 (20.2) | 13 (13.7) | 29 (44.6) |
| Yes | 1 (6.7) | 3 (1.8) | 9 (9.5) | 3 (4.6) |
| Missing Information | 10 (66.7) | 127 (77.9) | 73 (76.8) | 33 (50.8) |
| Chronic Lung Disease | ||||
| No History | 5 (33.3) | 32 (19.6) | 17 (17.9) | 28 (43.1) |
| Yes | 1 (6.7) | 4 (2.5) | 5 (5.3) | 5 (7.7) |
| Missing Information | 9 (60.0) | 127 (77.9) | 73 (76.8) | 32 (49.2) |
| Immunosuppressive Condition or Therapy** | ||||
| No History | 6 (40.0) | 39 (23.9) | 25 (26.3) | 33 (50.8) |
| Yes | 0 (0.0) | 1 (0.6) | 1 (1.1) | 0 (0.0) |
| Missing Information | 9 (60.0) | 123 (75.5) | 69 (72.6) | 32 (49.2) |
| Diabetes Mellitus | ||||
| No History | 6 (40.0) | 29 (17.8) | 18 (18.9) | 30 (46.2) |
| Yes† | 0 (0.0) | 0 (0.0) | 4 (4.2) | 1 (1.5) |
| Missing Information | 9 (60.0) | 134 (82.2) | 73 (76.8) | 34 (52.3) |
| Exposure Setting | ||||
| Private Home | 15 (100.0) | 2 (1.2) | 0 (0.0) | 1 (1.5) |
| Healthcare | 0 (0.0) | 161 (98.8) | 95 (100.0) | 0 (0.0) |
| Workplace (non-Healthcare) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 25 (38.5) |
| Transit / Transit Hub | 0 (0.0) | 0 (0.0) | 0 (0.0) | 37 (56.9) |
| Other | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (3.1) |
| Exposure Timeframe | ||||
| First exposed prior to symptom onset | 7 (46.7) | 0 (0.0) | 0 (0.0) | 2 (3.1) |
| First exposed on or after date of symptom onset | 8 (53.3) | 0 (0.0) | 0 (0.0) | 63 (96.9) |
| Investigation Procedures | ||||
| Development of New or Worsening Symptoms (Suspected COVID-19) | ||||
| No | 7 (46.7) | 138 (84.7) | 87 (91.6) | 57 (87.7) |
| Yes | 8 (53.3) | 25 (15.3) | 8 (8.4) | 8 (12.3) |
| Respiratory Sample Collection | ||||
| No samples | 0 (0.0) | 86 (52.8) | 72 (75.8) | 21 (32.3) |
| At least one set of samples | 15 (100.0) | 77 (47.2) | 23 (24.2) | 44 (67.7) |
| More than one set of samples | 15 (100.0) | 13 (8.0) | 3 (3.2) | 7 (10.8) |
*Includes healthcare or public health professionals providing patient care or directly interacting with a COVID-19 patient in healthcare setting; cleaning personnel who potentially had contact with bodily fluids of a COVID-19 patient in a healthcare setting; and laboratory personnel who processed samples without recommended PPE.
**Contacts were asked about any non-cancer immunosuppressive conditions or therapies (e.g., therapy for autoimmune conditions such as rheumatoid arthritis), as well as about whether cancer chemotherapy had been received within the last 12 months.
†All persons reporting a history of diabetes specified type 2 diabetes.